Scoop: Tur­ing is con­sid­er­ing a $100M cash of­fer for the drug that trig­gered a na­tion­al scan­dal over drug pric­ing

Tur­ing Phar­ma­ceu­ti­cals has re­ceived a $100 mil­lion of­fer for the drug that trig­gered a na­tion­al up­roar over drug price goug­ing, End­points News has learned.

The com­pa­ny, launched by Mar­tin Shkre­li be­fore he be­came a light­ning rod in the con­tro­ver­sy over ex­treme drug pric­ing, was sup­posed to gath­er votes to­day on pro­posed mem­bers of the board at Tur­ing. That vote was sched­uled af­ter re­search chief Eliseo Sali­nas took over re­cent­ly as in­ter­im CEO as var­i­ous fac­tions fought for con­trol of the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.